

## ORIGINAL ARTICLE

# The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy—A systematic review and meta-analysis

Allison L. Cirino<sup>1,2</sup>  | Stephanie L. Harris<sup>3</sup>  | Andrea M. Murad<sup>4</sup>  |  
Brittany Hansen<sup>5</sup>  | Jennifer Malinowski<sup>6</sup>  | Jaime L. Natoli<sup>7</sup> | Melissa A. Kelly<sup>8</sup>  |  
Susan Christian<sup>9</sup> 

<sup>1</sup>Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA

<sup>2</sup>MGH Institute of Health Professions, Boston, Massachusetts, USA

<sup>3</sup>Cardiovascular Genetics Program, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA

<sup>4</sup>Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

<sup>5</sup>Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA

<sup>6</sup>Write Inscite, South Salem, New York, USA

<sup>7</sup>Kaiser Permanente, Southern California Permanente Medical Group, Pasadena, California, USA

<sup>8</sup>Geisinger, Genomic Medicine Institute, Danville, Pennsylvania, USA

<sup>9</sup>Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada

## Correspondence

Allison L. Cirino, MGH Institute of Health Professions, 36 First Avenue, Boston, MA 02129.

Email: [acirino@mghihp.edu](mailto:acirino@mghihp.edu)

## Funding information

None.

## Abstract

Genetic testing and genetic counseling are routinely indicated for patients with hypertrophic cardiomyopathy (HCM); however, the uptake and utility of these services is not entirely understood. This systematic review and meta-analysis summarizes the uptake and utility of genetic counseling and genetic testing for patients with HCM and their at-risk family members, as well as the impact of genetic counseling/testing on patient-reported outcomes (PROs). A systematic search was performed through March 12, 2021. Meta-analyses were performed whenever possible; other findings were qualitatively summarized. Forty-eight studies met inclusion criteria (47 observational, 1 randomized). Uptake of genetic testing in probands was 57% (95% confidence interval [CI]: 40, 73). Uptake of cascade screening for at-risk relatives were as follows: 61% for cascade genetic testing (95% CI: 45, 75), 58% for cardiac screening (e.g. echocardiography) (95% CI: 40, 73), and 69% for either/both approaches (95% CI: 43, 87). In addition, relatives of probands with a positive genetic test result were significantly more likely to undergo cascade screening compared to relatives of probands with a negative result (odds ratio = 3.17, 95% CI: 2.12, 4.76). Overall, uptake of genetic counseling in both probands and relatives ranged from 37% to 84%. Multiple studies found little difference in PROs between individuals receiving positive versus negative genetic test results; however, other studies found that individuals with positive genetic test results experienced worse psychological outcomes. Genetic testing may also inform life choices, particularly decisions related to reproduction and insurance. Genetic counseling was associated with high satisfaction, increased perceived personal control and empowerment, and decreased anxiety. Approximately half to three-quarters of patients with HCM and their relatives undergo genetic testing or cascade screening. PROs after genetic testing varied and genetic counseling was associated with high satisfaction and improved PROs.

## KEYWORDS

cascade testing, genetic counseling, genetic testing, hypertrophic cardiomyopathy, predictive genetic testing, systematic review, utility

## 1 | INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant condition affecting approximately 1/500 individuals (Maron et al., 1995). The genetic basis of HCM was first established in 1990 (Geisterfer-Lowrance et al., 1990) and over the past two decades genetic testing and genetic counseling have become a recommended and routine part of clinical care for individuals with HCM (Hershberger et al., 2018; Landstrom et al., 2021; Ommen et al., 2021). Proband genetic testing can aid in confirmation of a diagnosis or distinguish HCM from various inherited or acquired phenocopies. Most importantly, proband genetic testing enables cascade genetic testing of at-risk relatives, which can identify relatives who are negative for the familial variant and can, therefore, avoid serial cardiac screening (e.g. echocardiography). In the absence of a causative variant, serial cardiac screening is recommended for all first-degree relatives of an individual diagnosed with HCM (Hershberger et al., 2018; Ommen et al., 2021).

Genetic counseling is defined as a 'process of helping patients understand and adapt to the medical, psychological and familial implications of genetic contributions to disease' (Resta et al., 2006). Genetic counselors provide genetics expertise, and patient education, as well as support patient's decision-making, adjustment to a new diagnosis, and communication of genetic risk to relatives. Cardiovascular genetic counselors are key members of the multidisciplinary teams caring for families with inherited cardiovascular disease (Ahmad et al., 2019; Musunuru et al., 2020).

Previous studies investigating outcomes of genetic testing and counseling in patients with HCM and their at-risk relatives have been limited to small patient cohorts using diverse methodologies. This systematic review summarizes data on the uptake and utility of genetic testing and genetic counseling for patients with HCM and their at-risk relatives, reviews the impact of these services on patient-reported outcomes (PROs), and identifies future research priorities. In addition, the findings of this review will serve as the basis for a forthcoming clinical practice guideline from the National Society of Genetic Counselors (NSGC).

## 2 | METHODS

The methods reported herein are part of a larger systematic evidence review (SER) to address the overarching research question, 'Do genetic testing and genetic counseling lead to improved outcomes for individuals diagnosed with HCM and their at-risk relatives?' A previous manuscript was published detailing the SER and meta-analysis for genetic testing detection rate, disease penetrance, and genotype-phenotype implications for prognosis (Christian et al., 2022). The present manuscript reports on the uptake of genetic testing by probands (defined as the percentage of index cases or affected individuals who had genetic testing), the uptake of cascade screening by at-risk relatives (defined as the percentage of at-risk relatives who had genetic testing, cardiac screening [e.g. echocardiography], or a combination of the two), the uptake of genetic counseling by

### What is known about this topic

Genetic testing and counseling are recommended for patients with HCM and their at-risk relatives; however, previous research on outcomes of genetic testing and counseling in this population have been limited to small patient cohorts using diverse methodologies.

### What this paper adds to the topic

This systematic evidence review and meta-analysis summarizes this data and identifies inadequacies in the uptake of cascade screening by at-risk relatives. Additionally, the uptake of genetic counseling is variable, but associated with high satisfaction and improved patient-reported outcomes.

probands and at-risk relatives (defined as the percentage of individuals who received genetic counseling), the influence of genetic testing on family communication and cascade screening, and PROs following genetic testing and genetic counseling. PROs included quality of life (QOL); psychological outcomes, such as illness perception, anxiety, depression, and distress; and knowledge, satisfaction, and life choices.

This SER is aligned to the PRISMA 2020 reporting statement (Page et al., 2021). The research team included genetic counselors, a methodologist, and medical librarians. The population, interventions, comparators, outcomes, timing, and setting (PICOTS) for the full HCM SER were predefined by the research team and are presented in Supporting Information S1a. The initial search was performed on July 7, 2017 and updated through March 12, 2021. Databases searched included PubMed (MEDLINE), Embase, CINAHL, and Cochrane Central Library; the search query for PubMed (MEDLINE) is presented in Supporting Information S1b. We also reviewed references of included studies and relevant studies known to the authors to identify other publications that may have been missed by the database searches.

All phases of the review, data extraction process, and quality assessment were performed by blinded reviewers in duplicate, with disagreements resolved through discussion or with the aid of a third reviewer. Quality assessment was evaluated for observational studies using the Newcastle-Ottawa tool, which takes the selection of the study cohort(s), the comparability of the study cohort(s), and the measurement of the study outcomes into account (Wells et al., 2013). For the randomized controlled trial, the Cochrane Risk of Bias tool was used to identify the potential for bias at all stages of the project from selection and allocation of the study cohorts to reporting of study outcomes (Higgins et al., 2011). Citations from the initial search queries were deduplicated and uploaded to Rayyan (Ouzzani et al., 2016) for review according to pre-specified inclusion and exclusion criteria (Supporting Information S2). The updated queries were uploaded to a Covidence project for screening and review. Relevant data was extracted into Excel spreadsheets by reviewers.

The data analysis plan was pre-specified and outcomes for probands and at-risk relatives were analyzed separately. Data analysis was performed using R (v. 4.0.2) with 'meta', 'metafor', and 'stats' packages (Balduzzi et al., 2019; R Core Team, 2021; Viechtbauer, 2010). Meta-analysis of continuous variables and multiple proportions were assessed using random-effects, inverse variance models, and meta-analyses of single proportions were calculated using random-effects, generalized linear mixed models (Schwarzer et al., 2019). All meta-analysis results are reported as the pooled estimates with accompanying 95% confidence intervals (CI) and *p*-values for between-group comparisons. Heterogeneity was calculated as  $I^2$  and  $\tau^2$  and are reported on the accompanying forest plots. Significance was set at  $p < 0.05$ ; no adjustment was made for multiple comparisons. If meta-analysis could not be performed for a particular outcome, data were narratively synthesized.

### 3 | RESULTS

For the overall HCM SER, a total of 4,662 non-duplicated abstracts were screened. Of these, 741 full-text articles were reviewed for possible inclusion, and 197 articles were accepted (Figure 1). Of the 197 publications, 149 articles focused on only detection rate, disease penetrance and genotype-phenotype implications for prognosis and are summarized by Christian et al. (2022). The present manuscript focuses on 48 publications that reported on uptake of genetic testing in probands (16 studies), uptake of cascade screening in at-risk relatives (25 studies), uptake of genetic counseling (7 studies), the influence of genetic testing on family communication (5 studies), PROs in probands (8 studies), and PROs in relatives (12 studies). A summary of all included studies is provided in Supporting Information S3. More comprehensive data, including quality assessments, are provided in Tables 1 and 2 and Supporting Information S4-S6.

#### 3.1 | Synthesis of evidence

##### 3.1.1 | Uptake of genetic testing in probands

Across 16 studies (10,770 individuals), the uptake of proband genetic testing was 57% (95% CI: 40, 73) and ranged from 13% to 99% (Figure 2; Supporting Information S2). Four studies specifically addressed the uptake of genetic testing in pediatric probands, which ranged from 13% to 44% (Alashi et al., 2021; Fitzgerald-Butt et al., 2010; Tunca Sahin et al., 2021; Zhu et al., 2020).

##### 3.1.2 | Uptake of cascade screening

Twenty-five studies (6,535 individuals) reported on the uptake of cascade screening in at-risk relatives, including uptake of genetic testing, cardiac screening, or a combination of the two (Figure 3; Supporting Information S5). Across 16 studies, the uptake of genetic

testing in at-risk relatives was 61% (95% CI: 45, 75) (Figure 3). Across five studies, the uptake of cardiac screening was 58% (95% CI: 40, 73), and across four studies the uptake of genetic testing and/or cardiac screening was 69% (95% CI: 43, 87) (Figure 3). An additional three studies, not included in the meta-analysis, reported on the uptake of cascade screening at a family level and uptake ranged from 56% to 73% (Christian et al., 2018; Knight et al., 2020; Ormondroyd et al., 2014) (Supporting Information S5).

Seven studies reported the uptake of genetic testing in pediatric patients at either an individual ( $n = 5$ ) or family level ( $n = 2$ ) and the results were highly variable, ranging from 8% to 93% (Charron et al., 2002; Christian et al., 2018; Jensen et al., 2013; Mathew et al., 2018; Norrish et al., 2019; Ormondroyd et al., 2014; van den Heuvel et al., 2020). One additional study found that 73% of families with at-risk children had cardiac screening and that cardiac screening occurred significantly more often in families when children had genetic testing (86% vs. 42%, respectively;  $p < 0.05$ ) (Christian et al., 2018). Another study found that 80% of children who underwent cascade genetic testing and were genotype-positive completed cardiac screening (Vermeer et al., 2017).


##### 3.1.3 | Uptake of genetic counseling

Seven studies (3,954 individuals) reported on the uptake of genetic counseling, which was delivered by a variety of healthcare providers, including genetic counselors, cardiologists, and nurses (Table 1). The uptake of genetic counseling ranged from 37% to 68% in probands (Hudson et al., 2019; Khouzam et al., 2015; Otten et al., 2015) and 38%-84% in at-risk relatives (Christiaans et al., 2008; Helio et al., 2020; Nieuwhof et al., 2017; van den Heuvel et al., 2020). Uptake of genetic counseling did not differ when counseling was provided by a genetic counselor/nurse versus a cardiologist (Nieuwhof et al., 2017). Finally, uptake of genetic counseling for pediatric patients was 56% (Christiaans et al., 2008; van den Heuvel et al., 2020).

##### 3.1.4 | Influence of proband genetic testing on family communication and cascade screening

Five studies (675 individuals) reported on the influence of proband genetic testing or genetic counseling on family communication (Supporting Information S6). Batte et al. (2015) reported that genetic test results were not a predictor of family communication. Similarly, one study reported that 96% of patients with a positive result and 100% of patients with a negative result shared their results with family members (Wynn et al., 2018). In another study, only a small percentage of probands reported that they did not communicate family screening recommendations with their relatives regardless of whether the proband pursued genetic testing (Harris et al., 2019). However, in interviews of probands who underwent genetic testing, family communication seemed less challenging for individuals with positive results compared to individuals with uninformative results

**FIGURE 1** PRISMA diagram. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) details the initial yield of the database searches and the process of selecting articles for inclusion in the systematic review



(Burns et al., 2017). An additional study found that awareness of family screening recommendations increased after genetic counseling (Ison et al., 2019).

Four studies (2,333 individuals) investigated the impact of proband genetic testing on the uptake of cascade screening (Figure 4; Supporting Information S5) (Harris et al., 2019; Knight et al., 2020; Ko et al., 2018; van der Roest et al., 2009). Across three studies, relatives of genotype-positive probands were more likely to have undergone cascade screening than relatives of genotype-negative probands (odds ratio = 3.17, 95% CI 2.12, 4.76) (Figure 4). Further, at a family level, Knight et al. (2020) found that uptake of cascade screening was significantly higher in families with a genotype-positive proband (90%) compared to families where the proband had a negative or inconclusive result (67%), or probands who did not pursue testing or for whom testing status was unknown (43%) ( $p < 0.001$ ).

### 3.1.5 | Patient-reported outcomes

Fifteen studies (1,235 patients) assessed the impact of genetic testing and genetic counseling on PROs for probands and at-risk relatives (Table 2).

#### Quality of life

Four studies investigated the impact of genetic testing on QOL (Christiaans et al., 2009b; Hickey et al., 2014; Ingles, Yeates, et al., 2012; Spanaki et al., 2016). Two studies suggested that there are no significant differences in QOL between probands or relatives with a positive versus negative genetic test result (Hickey et al., 2014; Ingles, Yeates, et al., 2012). Christiaans et al. (2009b) reported worse QOL scores on some subscales for affected individuals who had undergone genetic testing after their diagnosis compared to the general population and compared to genotype-positive relatives ( $p < 0.05$  and  $p < 0.05$ , respectively), some of whom were diagnosed with HCM after cascade genetic testing. Relatives who underwent cascade genetic testing did not have worse QOL than the general population, but relatives with a diagnosis of HCM after cascade genetic testing reported worse QOL on physical functioning and bodily pain subscales compared to genotype-positive, phenotype-negative relatives ( $p < 0.05$ ). A fourth study in a pediatric population found no difference in QOL in genotype-positive, phenotype-negative relatives compared to the general population (Spanaki et al., 2016). No studies investigated the impact of genetic counseling on QOL.

TABLE 1 Uptake of genetic counseling in probands and relatives

Study	Population group	% Uptake <sup>a</sup>	n	N	Families	Age group	Diagnoses included	Quality assessment
Christiaans et al. (2008)	First and second degree at-risk relatives	38	235	621	97	Both	HCM	Fair
		56	22 <sup>b</sup>	97 <sup>b</sup>	97	Ped		
Otten et al. (2015)	Probands	68	82	121	82	Adult	HCM, DCM	Very low/very poor
Khouzam et al. (2015)	Probands	37	113	306	-	Adult	HCM	Low/poor
Nieuwhof et al. (2017)	First degree relatives in GC/nurse group	79	87	111	-	>16 years old	HCM/DCM	High risk of bias
	First degree relatives in cardiologist group	71	102	144	-			
Hudson et al. (2019)	Probands	44	138	315	-	Both	HCM	Very low/very poor
Helio et al. (2020)	At-risk relatives	84	315	376	-	Adult	HCM, DCM, ARVC, RCM	Low/poor
	Probands and relatives	75	1,221	1,619	-		HCM	
van den Heuvel et al. (2020)	First and second degree at-risk relatives of deceased 1st degree relative	60	430	717	115	Both	HCM, LQTS, BrS, CPVT	Very low/very poor
	First degree relatives	63.7	381	598	-			
	Second degree relatives	41.2	49	119	-			
	First and Second degree at-risk relatives	55.9	19	34	-	<10 years old	HCM	

Note: Genetic counseling was provided by a variety of health care providers.

Abbreviations: ARVC, arrhythmogenic right ventricular cardiomyopathy; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; RCM, restrictive cardiomyopathy.

<sup>a</sup>Data are from clinic cohorts with the exception of Khouzam et al. and Hudson et al., which both gathered self-reported data from a patient advocacy group cohort.

<sup>b</sup>Number of families who had genetic testing.

**TABLE 2** Patient-reported outcomes in probands and relatives

Study	Population	Age group	Diagnoses included	GT/GC	n	PRO	Instrument	Study findings	Quality assessment
<i>Quality of life</i>									
<i>Probands</i>									
Hickey et al. (2014)	Affected individuals w/ prior GT	Adult	HCM, DCM, ARVC, LQTS, BrS	GT	58 Total (24 HCM)	HRQL	SF-36	G+ individuals scored worse on the bodily pain dimension than G- ( $p = 0.046$ ) but did not fall below the normal range for the general population. There were no other differences in HRQL between G+ and G-	Very low/very poor
<i>Probands and relatives</i>									
Christians et al. (2009b)	Group 1: G+ probands and relatives diagnosed before GT Group 2: G+ relatives diagnosed after GT Group 3: G+/P- relatives	>16 years old	HCM	GT	228	HRQL	SF-36	Group 1 scored worse on all subscales, except the mental well-being subscale and mental component, when compared to Groups 2 and 3 ( $p < 0.05$ ). Group 2 had worse HRQL than Group 3 on the physical functioning and bodily pain subscales and the physical component ( $p < 0.05$ ). Group 1 scored worse than the general population on 4/8 subscales and the physical component ( $p < 0.05$ ). Groups 2 and 3 did not have worse HRQL the general population. In Groups 2 and 3 combined, only the perceived risk of developing symptoms was an independent determinant of mental scores ( $p = 0.035$ )	Fair
Ingles et al. (2012)	Group 1: G+ probands Group 2: Proband w/VUS Group 3: G+/P- relatives Group 4: G- relatives	>15 years old	HCM, DCM, ARVC, LQTS	GT	54 Total (33 probands and 21 relatives)	HRQL	SF-36, v2	No difference between baseline and post-GT results (1-3 months and 12 months) scores when comparing Groups 1 and 2 or Groups 3 and 4 ( $p > 0.05$ )	Fair
<i>Relatives</i>									
Spanaki et al. (2016)	G+/P- relatives (Group G <sup>+</sup> )	Pediatric	HCM	GT	23	QoL	PedsQL	No difference between G+/P- relatives and the normative population ( $p = 0.7$ )	Very low/very poor
<i>Psychological outcomes</i>									
<i>Proband</i>									
Hickey et al. (2014)	Affected individuals with prior GT	Adult	HCM, DCM, ARVC, LQTS, BrS	GT	58 Total (24 HCM)	Anxiety, depression	HADS	Anxiety and depression did not differ between G+ and G- participants (anxiety 29.4% vs. 28.6%, depression 11.8% vs. 0%)	Very low/very poor
Otten et al. (2015)	Probands with no prior GT or GC	Adult	HCM, DCM	GC	121	Anxiety	IPQ-R Dutch-short version STAI Dutch PPC	Positive GT results did not impact scores, nor did it impact perceived risks for serious cardiac events, developing additional cardiac symptoms, and limitations due to their illness Anxiety decreased after the group GC session compared to pre-session levels ( $p < 0.001$ ) PPC increased after attending a group GC session compared to pre-session levels ( $p < 0.001$ )	Very low/very poor

(Continues)

TABLE 2 (Continued)

Study	Population	Age group	Diagnoses included	GT/GC	n	PRO	Instrument	Study findings	Quality assessment
Christiaans et al. (2009b)	Group 1: G+ probands and relatives Group 2: G+ relatives diagnosed before GT Group 3: G+/P- relatives diagnosed after GT	>16 years old	HCM	GT	228	Anxiety, depression	HADS	Group 1 scored worse on the depression subscale than Groups 2 and 3 combined ( $p < 0.05$ ), but not anxiety scores. Groups 1, 2 + 3 combined had lower anxiety scores than the general population ( $p < 0.05$ ). Groups 2 + 3 combined had lower anxiety and depression scores than the general population ( $p < 0.05$ and $p < 0.05$ , respectively), as did Group 3 only when compared to the general population ( $p < 0.05$ and $p < 0.05$ , respectively)	Low/poor
Hamang et al. (2012)	Probands and relatives	>17 years old	HCM, LQTS	GT/GC	126	Heart-focused anxiety	CAQ	Scores were higher in diagnosed vs. at-risk individuals ( $p = 0.002$ – $0.303$ across multiple subscales and timepoints). Satisfaction with GC was associated with lower cardio-protective avoidance and heart-focused attention scores ( $p = 0.037$ and $0.024$ , respectively). A positive GT result was associated with higher avoidance scores at 6 months post GC ( $p = 0.032$ )	Very low/very poor
Wynn et al. (2018)	1. G+ probands 2. G- probands 3. G+ relatives 4. G- relatives 5. Probands and relatives with a VUS	Adult	HCM, DCM	GT	Total: 90 Group 1: 38 Group 2: 9 Group 3: 14 Group 4: 24 Group 5: 5	Distress, uncertainty, positivity	aMICRA	Regardless of CM status, total scores, and all subdomain scores (uncertainty, distress, and positivity) were worse for G+ than G- ( $p < 0.0001$ , $p < 0.0001$ , $p < 0.0001$ , and $p = 0.004$ , respectively). Non-probands had better total scores and less uncertainty and distress than probands ( $p = 0.002$ , $p = 0.002$ and $p = 0.001$ , respectively). Participants with a VUS had worse total scores and less positivity than G- participants ( $p = 0.036$ and $p < 0.001$ , respectively)	Very low/very poor
Ison et al. (2019)	Probands and relatives	Adult	HCM, FH, DCM, SCA, LQTS, Other	GC	42	Empowerment	GCOS	Regardless of CM status, total scores and all subdomain scores (intrusiveness, avoidance, and hyperarousal) were worse for G+ than G- participants ( $p = 0.001$ , $p = 0.001$ , $p = 0.004$ , respectively). Non-probands had better total scores and better intrusive, avoidance, and hyperarousal subscale scores than probands ( $p = 0.008$ , $p = 0.03$ , $p = 0.04$ and $p = 0.002$ , respectively). There was no difference in total scores and intrusive, avoidance, and hyperarousal subscale scores between G- participants and those with a VUS ( $p = 0.86$ , $p = 0.70$ , $p = 0.81$ and $p = 0.54$ , respectively) Scores increased following GC ( $p < 0.0001$ )	Very low/very poor

TABLE 2 (Continued)

Study	Population	Age group	Diagnoses included	GT/GC	n	PRO	Instrument	Study findings	Quality assessment
Relatives									
Charron et al. (2002)	1. Adults undergoing predictive GT 2. Parents discussing predictive GT for children	Adult	HCM	GT	Group 1: 19 Group 2: 9	Anxiety, depression	Interviews	16% of adults who had predictive GT had adverse event (sub depressive syndrome in G+, mild hypochondriac symptoms in G+, increased anxiety in G-). The one child who had predictive GT had an adverse event (transient panic attack in G+)	Low/poor
Jensen et al. (2013)	1. G+ relatives 2. G- relatives 3. Relatives with unknown risk status	Pediatric	HCM	GT	66	Anxiety, depression	STAI, HADS, IES and DS14	No difference in outcomes was observed between the G- relatives, G+ relatives and relatives with unknown genetic status	Low/poor
MacLeod et al. (2014)	Individuals having predictive GT	15-25 years old	HD, HBOC, HCM, DCM	GT	10 (HCM and DCM) 10 (HD) 16 (HBOC)	Psychosocial impact	Interviews	Participants felt prepared for a positive result, but also expressed shock, which was variable in duration. Most recalled feeling ready to proceed with GT and indicated that while their parents and healthcare professions expressed that testing would be useful, it was not intrusive	Very low/very poor
Nieuwhof et al. (2017)	P- relatives of probands with or without a proven genetic cause	>16 years old	HCM, DCM	GC	189	PPC	Dutch PPC	There was no difference in scores between patients who had visits with a GC/nurse vs. cardiologist ( $p = 0.39$ )	High risk of bias
Bonner et al. (2018)	Relatives eligible for predictive testing	Adult	HCM	GT	32	Psychosocial impact	Interviews	While most participants felt the GT result had minimal psychosocial impact, there were a variety of psychosocial impacts reported and the degree of impact may relate to perceived risk and the requirement for behavioral change	Very low/very poor
Knowledge, satisfaction, and life changes									
Proband									
Otten et al. (2015)	Probands with no prior GT or GC	Adult	HCM, DCM	GC	121	Satisfaction	CGS	Participants were satisfied with group GC and there was no difference between small or large group. ~74% of patients were satisfied with the content and design of the group session, 87.7% would get GC again if indicated and 81.4% would recommend it to family	Very low/very poor
Burns et al. (2017)	Probands with prior GT (G+, G-, VUS)	Adult	HCM	GT	19	Knowledge	Interviews	Knowledge and recall were dependent on the result classification. Individuals with an uninformative result had the poorest understanding and recall	Good
Probands and relatives									
Hamang et al. (2012)	Probands and relatives	>17 years old	HCM, LQTS	GC		Satisfaction	Satisfaction with GC Scale	Patients reported a high level of satisfaction with GC across the instrumental, affective, and procedural subscales	Very low/very poor



TABLE 2 (Continued)

Study	Population	Age group	Diagnoses included	GT/GC	n	PRO	Instrument	Study findings	Quality assessment
Wynn et al. (2018)	1. G+ probands 2. G- probands 3. G+ relatives 4. G- relatives 5. Probands and relatives with VUS	Adult	HCM, DCM	GT	90	Satisfaction	SWD scale	79% reported satisfaction with the decision to have GT; this did not differ based on GT results or proband status. Those without cardiac symptoms had lower odds of satisfaction with the decision to test than those with symptoms (OR 0.87, 95% CI 0.76–0.99, $p = 0.04$ )	Very low/very poor
Christiaans et al. (2009a)	G+ relatives	>16 years old	HCM	GT, GC	123	Satisfaction, social pressure, regret	Novel questionnaire	34% either made or planned a life change based on their GT results. G+ more frequently made life changes than G- (44% vs. 18%, $p = 0.01$ ), including having a biological child (2.6% vs. 9%) and obtaining new life insurance (16% vs. 9%)	Low/poor
MacLeod et al. (2014)	Individuals having predictive GT	15–25 years old	HD, HBOC, HCM, DCM	GT, GC	10 (HCM and DCM) 10 (HD) 16 (HBOC)	Life change	Interviews	High scores for satisfaction with information provision and satisfaction with counseling. Scores for social pressure to test and regret of testing were low, meaning participants were less likely to report either. Factors associated with higher GC satisfaction were: older age, having a partner and/or comorbidity, 95% were happy with the way they received their results. Lower satisfaction scores were reported by those who received their results in clinic compared to mail or phone ( $p = 0.032$ )	Very low/very poor
Nieuwhof et al. (2017)	P- relatives of probands with or without a proven genetic cause	>16 years old	HCM, DCM	GC	189	Satisfaction, regret	Satisfaction Indicator <sup>b</sup>	Participants did not regret their decision to have GT in young adulthood. Overall, participants were satisfied with GC, more as a source of accessible information than to facilitate decision-making	Very low/very poor
Bonner et al. (2018)	Relatives eligible for predictive testing	Adult	HCM	GT	32	Life change	Interviews	Participants seen in GC/nurse clinic more often reported the maximum patient satisfaction score compared to patients seen in cardiology clinic (86% vs. 45%, $p < 0.01$ )	Very low/very poor

Note: Other: Born with ventricular septal defect, sudden cardiac death, heart attack, pulmonary arterial hypertension.

Abbreviations: aMICRA, multidimensional impact of cancer risk assessment; ARVC, arrhythmogenic right ventricular cardiomyopathy; BrS, Brugada syndrome; CAQ, Cardiac Anxiety Questionnaire; CGS, clinical genetics satisfaction indicator; CM, cardiomyopathy; DCM, dilated cardiomyopathy; DS14, standard assessment of negative affectivity; FH, familial hypercholesterolemia; G+, positive genetic-test result; G-, negative genetic-test result; GC, genetic counseling; GCOS, Genetic Counseling Outcome Scale; GT, genetic testing; HADS, Hospital Anxiety and Depression Scale; HBOC, hereditary breast and ovarian cancer; HCM, hypertrophic cardiomyopathy; HD, Huntington's disease; HRQL, health-related quality of life; IES, impact of events scale; IPQ-R, Illness Perception Questionnaire, Revised; LQTS, long QT syndrome; P-, phenotype negative; PPC, perceived personal control; PRO, patient-reported outcome; QoL, quality of life; SCA, sudden cardiac arrest; STAI, State-Trait Anxiety Inventory; SWD, Satisfaction with decision scale; VUS, variant of uncertain significance.

<sup>a</sup>Data from Groups A and S was excluded because patients with syndromic disease were included.

<sup>b</sup>Satisfaction Indicator of the Dutch Clinical Genetics Association (VKGn).




FIGURE 2 Uptake of genetic testing in probands. Forest plot of the proportion of probands who underwent genetic testing




FIGURE 3 Uptake of cascade screening in at-risk relatives. Forest plot of the proportion of at-risk family members who underwent genetic testing, cardiac screening or a combination of either screening modality




FIGURE 4 Impact of proband genetic testing on cascade screening. Forest plot of studies reporting the uptake of cascade screening among at-risk relatives of genotype-positive probands compared to at-risk relatives of genotype-negative probands

### Psychological outcomes

Eight studies reported on psychological outcomes of probands and relatives undergoing genetic testing (Bonner et al., 2018; Charron et al., 2002; Christiaans et al., 2009b; Hamang et al., 2012; Hickey et al., 2014; Jensen et al., 2013; MacLeod et al., 2014; Wynn et al., 2018). Hickey et al. (2014) found that illness perception, anxiety, and depression did not differ in probands with a positive versus negative genetic test result. However, Wynn et al. (2018) assessed psychological outcomes in probands and relatives who had undergone genetic testing and found that patients with a positive genetic test result, regardless of cardiomyopathy status, had greater distress and uncertainty and less positivity than patients with a negative result ( $p < 0.001$ ,  $p < 0.001$ ,  $p = 0.004$ , respectively). Also, regardless of cardiomyopathy status patients with a positive genetic test result experienced more intrusive thoughts, avoidance, and hyperarousal than those with a negative result ( $p = 0.001$ ,  $p = 0.04$ ,  $p = 0.0004$ ).

Christiaans et al. (2009b) reported that affected individuals who had undergone genetic testing experienced more depression than genotype-positive relatives, some of whom were diagnosed with HCM after cascade genetic testing ( $p < 0.05$ ), but there was no significant difference in anxiety and both groups had lower anxiety scores than the general population. Hamang et al. (2012) found that individuals with a positive genetic test result had higher levels of cardio-protective avoidance ( $p = 0.032$ ). Multiple interview-based studies found that most at-risk relatives reported minimal psychological impact after cascade genetic testing, although some individuals experienced shock when receiving their result or worry about their children (Bonner et al., 2018; Charron et al., 2002; MacLeod et al., 2014). Jensen et al. (2013) measured anxiety and depression in three pediatric groups: genotype-negative relatives, genotype-positive relatives, and relatives of individuals with unknown genetic status; they found no significant differences in outcomes among the three groups.

Four studies investigated the impact of genetic counseling on psychological outcomes in probands and at-risk relatives (Hamang et al., 2012; Ison et al., 2019; Nieuwhof et al., 2017; Otten et al., 2015). One study found that probands had increased perceived personal control (PPC) and lower anxiety after group genetic counseling (Otten et al., 2015). Another study assessed PPC in at-risk relatives after genetic counseling when counseling was provided by a genetic counselor/nurse versus a cardiologist and found

no significant difference between groups (Nieuwhof et al., 2017). Hamang et al. (2012) found that satisfaction with genetic counseling was associated with lower cardiac-related avoidance and attention ( $p = 0.037$  and  $p = 0.024$ , respectively). Ison et al. (2019) found a significant increase in empowerment in probands and relatives after genetic counseling ( $p < 0.0001$ ).

### Knowledge, satisfaction, and life choices

Five studies investigated the impact of genetic testing on knowledge, satisfaction, and life choices (Bonner et al., 2018; Burns et al., 2017; Christiaans et al., 2009a; MacLeod et al., 2014; Wynn et al., 2018). In interviews, Burns et al. (2017) found that probands with positive results expressed better understanding of their results compared to individuals with uninformative results. Wynn et al. (2018) assessed satisfaction in probands and relatives and found that 79% of participants reported complete satisfaction with the decision to have genetic testing, regardless of genetic test results or proband status, although satisfaction was lower in individuals without cardiac symptoms compared to individuals with symptoms ( $p = 0.04$ ). The same study reported that 34% of individuals reported having made or were planning to make a life change after genetic testing, most often having a biological child and obtaining new life insurance. Participants with positive results more frequently made life changes compared to participants with negative results ( $p = 0.01$ ). MacLeod et al. (2014) and Bonner et al. (2018) also found that at-risk relatives undergoing cascade genetic testing found the information helpful for reproductive and insurance planning, as well as to guide exercise. Christiaans et al. (2009a) found that at-risk relatives did not experience pressure to proceed with cascade genetic testing or regret after testing.

Five studies assessed probands and relative's satisfaction with genetic counseling, with all studies reporting high levels of satisfaction (Christiaans et al., 2009a; Hamang et al., 2012; MacLeod et al., 2014; Nieuwhof et al., 2017; Otten et al., 2015). Nieuwhof et al. (2017) found that satisfaction was significantly greater for patients who received genetic counseling from a genetic counselor/nurse versus a cardiologist.

### 3.1.6 | Quality assessment and risk of bias

The 48 studies included in this SER consisted of 47 observational studies and one randomized trial. The quality of individual studies

using Newcastle-Ottawa tool was mostly low/poor or very low/very poor. Factors that contribute to a rating of 'poor quality' or 'high risk of bias' include: bias in measurement of the outcome, missing/bias in selection of the reported outcome data, and lack of representativeness of the study population to the population of interest. Studies included in this review varied in their methodologies (quantitative vs. qualitative, retrospective vs. prospective), reported outcomes and measurement of those outcomes as well as cohort recruitment and inclusion criteria (participants with other inherited diagnoses, participants ascertained through clinic vs. patient advocacy organizations, relatives ascertained via consultation vs. pedigree analysis). While we did not exclude studies deemed to be of 'poor quality' or 'high risk of bias', the results reported in these studies may be less certain than the results reported by studies assessed as good quality or with a low risk of bias.

## 4 | DISCUSSION

### 4.1 | Summary of evidence

Hypertrophic cardiomyopathy is a routine indication for genetic testing and genetic counseling. However, our SER and meta-analyses found that only half to three-quarters of patients with HCM and their relatives undergo genetic testing or cascade screening. Furthermore, the reported uptake of genetic counseling was highly variable, but genetic counseling was associated with high satisfaction and improved PROs. Our results highlight the need for novel mechanisms to improve the uptake of genetic testing, cascade screening and genetic counseling for families with HCM.

Although just over half of probands completed genetic testing, uptake varied considerably across studies, which may reflect differing genetic testing trends based on year, country, healthcare system, patient ascertainment, and demographics. Notably, few studies focused on probands' decision to pursue genetic testing. Khouzam et al. (2015) found that individuals were more likely to pursue testing if they were evaluated by a genetics professional, had a relative with HCM, had a known variant in the family, or if they perceived certain benefits to genetic testing such as it would satisfy curiosity, provide reassurance, guide healthcare decisions, or serve as a motivator for a healthier lifestyle. Other factors that may influence the decision to pursue testing include education level and understanding of the inherited nature of HCM, as well as concerns about cost, insurance coverage, and genetic discrimination (Fitzgerald-Butt et al., 2010; Khouzam et al., 2015; Murphy et al., 2016). Uptake of genetic counseling by probands and at-risk relatives varied dramatically. Notably only one study specifically reported on the uptake of genetic counseling by a genetic counselor/nurse (Nieuwhof et al., 2017), highlighting the need for further research investigating access to and utilization of genetic counselors versus other health professionals.

Cascade screening in families with HCM is critical to identify relatives with subclinical disease who are at risk for sudden cardiac death (SCD), heart failure, or stroke. When a genetic diagnosis is established in a family, cascade genetic testing can discriminate between relatives requiring serial cardiac screening and those who can be released from routine cardiac care. Our data demonstrates that the uptake of cascade screening is approximately 60%–70%; thus, approximately a third of at-risk relatives do not seek care related to their family history of HCM. Reasons for not completing cascade screening are poorly understood. Studies suggest most probands share genetic risk information with their relatives regardless of genetic testing status or result (Batte et al., 2015; Harris et al., 2019; Wynn et al., 2018); however, a positive genetic test result in a proband is associated with greater uptake of cascade screening in their relatives, possibly indicating that a proband's positive result motivates at-risk relatives to seek evaluation.

These findings underscore the need for novel methods for disseminating genetic risk information in families and equipping relatives to act on this information. Numerous studies have investigated the acceptability and utility of direct-contact methods and technology interventions to assist with cascade screening (Haas et al., 2021; Jujavarapu et al., 2021; Schmidlen et al., 2019; Sturm, 2016), and such approaches should continue to be explored. Although not specifically analyzed in this review, we identified five studies demonstrating the cost-effectiveness of genetic testing and cascade screening for HCM, derived from cessation of cardiac screening for genotype-negative relatives. These findings further highlight the benefit of genetic testing and cascade screening, not just for families, but for healthcare systems at large (Alejandra Restrepo-Cordoba et al., 2017; Alfares et al., 2015; Ingles, McGaughan, et al., 2012; Tomasov et al., 2014; Wordsworth et al., 2010).

Fifteen studies investigated the influence of genetic testing and genetic counseling on PROs, but these studies varied considerably in study design, cohort, outcomes and measures. Multiple studies found little difference in PROs between individuals receiving positive versus negative genetic test results (Hickey et al., 2014; Ingles, Yeates, et al., 2012; Jensen et al., 2013) suggesting that genetic test results may not contribute to worse outcomes. However, other studies reported worse psychological outcomes in individuals with a positive genetic test result, and importantly Wynn et al. (2018) found this to be true regardless of cardiomyopathy status (Hamang et al., 2012). Other studies suggested that worse outcomes may be related to having a clinical diagnosis of HCM or symptoms related to the disease (Christiaans et al., 2009b). A recent systematic review concluded that genetic testing across a diverse group of inherited cardiovascular disorders does not negatively impact QOL nor increase anxiety and distress (Oliveri et al., 2018). Additional research is needed to better understand predictors of worse psychological outcomes among individuals undergoing genetic testing for HCM.

Multiple studies noted that genetic testing may help guide life choices, including reproductive and insurance planning, and this may happen more often for individuals with a positive genetic test result (Bonner et al., 2018; MacLeod et al., 2014; Wynn et al., 2018).

Additionally, studies reported high satisfaction with genetic counseling (Christiaans et al., 2009a; Hamang et al., 2012; Nieuwhof et al., 2017; Otten et al., 2015; Wynn et al., 2018) and found that genetic counseling was associated with increased PPC and empowerment and decreased anxiety (Hamang et al., 2012; Ison et al., 2019; Otten et al., 2015). These findings suggest that genetic counseling is associated with improved PROs, although further research is needed to understand which patients may benefit most from genetic counseling and the impact of various genetic counseling service delivery models.

## 4.2 | Limitations and future direction

All but one study included in this review were observational. Although large, randomized trials are often considered to be the most rigorous approach to answering questions about the impact of testing and medical interventions on patient outcomes, they may have limited applicability for questions that relate to rare diseases such as HCM as well as interventions that are heavily dependent on patient preferences and autonomy. Secondly, many study cohorts were small or included participants with other inherited diagnoses. It is possible that conclusions drawn from studies including cohorts of patients with various conditions may not be generalizable to strictly HCM populations. For some outcomes, particularly uptake of proband genetic testing, the outcome was not the primary focus of most of the studies included in this analysis. Studies assessing the uptake of cascade screening varied in their ascertainment of at-risk relatives, with some studies only including relatives that presented for consultation. Lastly, studies investigating relevant outcomes in patients with a variety of inherited diseases including HCM may not have been identified in our search.

Making comparisons and combining data across studies for analysis is limited by varying methodologies, inconsistent definitions and different outcomes of interest and measures. Collaboration by international cardiovascular genetics teams to prioritize outcomes of interest, define the optimal way to measure these outcomes, and harmonize data collection across institutions would strengthen research on the uptake and utility of genetic counseling and testing. Such collaborations would also allow for collection of disease-specific data with sufficient sample size to provide meaningful results.

## 5 | CONCLUSIONS

As genetic testing and genetic counseling have become routinely incorporated into the clinical care of patients with HCM and their relatives, numerous studies have investigated the impact of these services. This SER synthesizes the existing research on uptake and utility of genetic testing and genetic counseling for HCM. Overall, the findings suggest that many probands do not undergo genetic

testing and many at-risk relatives do not undergo cascade screening. While the uptake of genetic counseling varied, satisfaction with genetic counseling was high. Lastly, though studies had inconsistent findings, most studies indicate that genetic testing does not lead to worse PROs and genetic counseling may improve PROs.

This SER highlights future research needs, including studies focused on probands' decision-making around genetic testing, novel methods for promoting cascade screening, factors influencing psychological outcomes after genetic testing, and outcomes related to genetic counseling services, specifically when delivered by a genetic counselor. Importantly, future research would be strengthened by collaboration across cardiovascular genetic teams, ensuring systematic collection of outcomes using consistently defined variables and standardized reporting. When appropriate, more rigorous study designs, such as randomized control trials, could be considered. The study outcomes summarized herein have relevance for genetic counseling practice and as such, genetic counselors should play a central role in generating high quality genetic counseling research. The findings of this review will serve as the basis for a forthcoming National Society of Genetic Counselors clinical practice guideline.

### AUTHOR CONTRIBUTIONS

**Allison L Cirino:** Conceptualization; data curation; formal analysis; writing – original draft. **Stephanie L. Harris:** Conceptualization; data curation; formal analysis; writing – original draft. **Andrea M. Murad:** Conceptualization; data curation; formal analysis; writing – review and editing. **Brittany Hansen:** Conceptualization; data curation; formal analysis; writing – review and editing. **Jennifer Malinowski:** Formal analysis; methodology; visualization; writing – review and editing. **Jaime L. Natoli:** Conceptualization; methodology; writing – review and editing. **Melissa A. Kelly:** Conceptualization; data curation; formal analysis; writing – review and editing. **Susan Christian:** Conceptualization; data curation; formal analysis; writing – original draft; writing – review and editing.

### ACKNOWLEDGMENTS

The authors would like to acknowledge Talin Boghosian's contributions to this project. Support for Jennifer Malinowski's time was provided by the National Society of Genetic Counselors (NSGC). We want to thank the NSGC Practice Guidelines Committee for identifying the need for this systematic review and supporting this project.

### COMPLIANCE WITH ETHICAL STANDARDS

### CONFLICT OF INTEREST

All authors declare no conflicts of interest.

### HUMAN STUDIES AND INFORMED CONSENT

No human studies were carried out by the authors of this article.

### ANIMAL STUDIES

No non-human animal studies were carried out by the authors for this article.

## DATA SHARING AND DATA ACCESSIBILITY

The data that supports the findings of this study are available in the supplementary material of this article.

## ORCID

Allison L. Cirino  <https://orcid.org/0000-0002-7115-9532>

Stephanie L. Harris  <https://orcid.org/0000-0002-4222-6767>

Andrea M. Murad  <https://orcid.org/0000-0003-0423-4966>

Brittany Hansen  <https://orcid.org/0000-0001-8810-6763>

Jennifer Malinowski  <https://orcid.org/0000-0001-7500-2199>

Melissa A. Kelly  <https://orcid.org/0000-0003-4708-2261>

Susan Christian  <https://orcid.org/0000-0001-5248-3049>

## REFERENCES

- Ahmad, F., McNally, E. M., Ackerman, M. J., Baty, L. C., Day, S. M., Kullo, I. J., Madueme, P. C., Maron, M. S., Martinez, M. W., Salberg, L., Taylor, M. R., & Wilcox, J. E. (2019). Establishment of specialized clinical cardiovascular genetics programs: Recognizing the need and meeting standards: A scientific statement from the American Heart Association. *Circulation. Genomic and Precision Medicine*, 12(6), e000054. <https://doi.org/10.1161/HCG.0000000000000054>
- Alashi, A., Svensson, L., Klein, J., Zahka, K., Smedira, N. G., Najm, H., Lever, H. M., Aziz, P., & Desai, M. Y. (2021). Characteristics and longer-term outcomes of contemporary patients <18 years of age with hypertrophic cardiomyopathy. *The American Journal of Cardiology*, 140, 110–117. <https://doi.org/10.1016/j.amjcard.2020.10.060>
- Alejandra Restrepo-Cordoba, M., Campuzano, O., Ripoll-Vera, T., Cobo-Marcos, M., Mademont-Soler, I., Gamez, J. M., Dominguez, F., Gonzalez-Lopez, E., Padron-Barthe, L., Lara-Pezzi, E., Alonso-Pulpon, L., Brugada, R., & Garcia-Pavia, P. (2017). Usefulness of genetic testing in hypertrophic cardiomyopathy: An analysis using real-world data. *Journal of Cardiovascular Translational Research*, 10(1), 35–46. <https://doi.org/10.1007/s12265-017-9730-8>
- Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., Cox, S. W., DePalma, S. R., Ho, C. Y., Seidman, J. G., Seidman, C. E., & Rehm, H. L. (2015). Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity. *Genetics in Medicine*, 17(11), 880–888. <https://doi.org/10.1038/gim.2014.205>
- Balduzzi, S., Rücker, G., & Schwarzer, G. (2019). How to perform a meta-analysis with R: A practical tutorial. *Evidence-Based Mental Health*, 22, 153–160.
- Batte, B., Sheldon, J. P., Arscott, P., Huismann, D. J., Salberg, L., Day, S. M., & Yashar, B. M. (2015). Family communication in a population at risk for hypertrophic cardiomyopathy. *Journal of Genetic Counseling*, 24(2), 336–348. <https://doi.org/10.1007/s10897-014-9774-8>
- Bonner, C., Spinks, C., Semsarian, C., Barratt, A., Ingles, J., & McCaffery, K. (2018). Psychosocial impact of a positive gene result for asymptomatic relatives at risk of hypertrophic cardiomyopathy. *Journal of Genetic Counseling*, 27(5), 1040–1048. <https://doi.org/10.1007/s10897-018-0218-8>
- Burns, C., Yeates, L., Spinks, C., Semsarian, C., & Ingles, J. (2017). Attitudes, knowledge and consequences of uncertain genetic findings in hypertrophic cardiomyopathy. *European Journal of Human Genetics*, 25(7), 809–815. <https://doi.org/10.1038/ejhg.2017.66>
- Charron, P., Heron, D., Gargiulo, M., Richard, P., Dubourg, O., Desnos, M., Bouhour, J. B., Feingold, J., Carrier, L., Hainque, B., Schwartz, K., & Komajda, M. (2002). Genetic testing and genetic counselling in hypertrophic cardiomyopathy: The French experience. *Journal of Medical Genetics*, 39(10), 741–746. <https://doi.org/10.1136/jmg.39.10.741>
- Christiaans, I., Birnie, E., Bonsel, G. J., Wilde, A. A., & van Langen, I. M. (2008). Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. *European Journal of Human Genetics*, 16(10), 1201–1207. <https://doi.org/10.1038/ejhg.2008.92>
- Christiaans, I., van Langen, I. M., Birnie, E., Bonsel, G. J., Wilde, A. A., & Smets, E. M. (2009a). Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: The patients' perspective. *American Journal of Medical Genetics. Part A*, 149A(7), 1444–1451. <https://doi.org/10.1002/ajmg.a.32915>
- Christiaans, I., van Langen, I. M., Birnie, E., Bonsel, G. J., Wilde, A. A., & Smets, E. M. (2009b). Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A cross-sectional cohort study. *American Journal of Medical Genetics. Part A*, 149A(4), 602–612. <https://doi.org/10.1002/ajmg.a.32710>
- Christian, S., Atallah, J., Clegg, R., Giuffre, M., Huculak, C., Dzwiniel, T., Parboosingh, J., Taylor, S., & Somerville, M. (2018). Uptake of predictive genetic testing and cardiac evaluation for children at risk for an inherited arrhythmia or cardiomyopathy. *Journal of Genetic Counseling*, 27(1), 124–130. <https://doi.org/10.1007/s10897-017-0129-0>
- Christian, S., Cirino, A., Hansen, B., Harris, S., Murad, A. M., Natoli, J. L., Malinowski, J., & Kelly, M. A. (2022). Diagnostic validity and clinical utility of genetic testing for hypertrophic cardiomyopathy: A systematic review and meta-analysis. *Open Heart*, 9(1), e001815. <https://doi.org/10.1136/openhrt-2021-001815>
- Fitzgerald-Butt, S. M., Byrne, L., Gerhardt, C. A., Vannatta, K., Hoffman, T. M., & McBride, K. L. (2010). Parental knowledge and attitudes toward hypertrophic cardiomyopathy genetic testing. *Pediatric Cardiology*, 31(2), 195–202. <https://doi.org/10.1007/s00246-009-9583-2>
- Geisterfer-Lowrance, A. A., Kass, S., Tanigawa, G., Vosberg, H. P., McKenna, W., Seidman, C. E., & Seidman, J. G. (1990). A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. *Cell*, 62(5), 999–1006. [https://doi.org/10.1016/0092-8674\(90\)90274-i](https://doi.org/10.1016/0092-8674(90)90274-i)
- Haas, C. B., Scrol, A., Ujjavarapu, C., Jarvik, G. P., & Henrikson, N. B. (2021). Usefulness of mobile apps for communication of genetic test results to at-risk family members in a U.S. integrated health system: A qualitative approach from user-testing. *Health Policy and Technology*, 10(2), 100511. <https://doi.org/10.1016/j.hlpt.2021.100511>
- Hamang, A., Eide, G. E., Rokne, B., Nordin, K., Bjorvatn, C., & Oyen, N. (2012). Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long QT syndrome or hypertrophic cardiomyopathy: A one year follow-up. *Journal of Genetic Counseling*, 21(1), 72–84. <https://doi.org/10.1007/s10897-011-9393-6>
- Harris, S., Cirino, A. L., Carr, C. W., Tafessu, H. M., Parmar, S., Greenberg, J. O., Szent-Gyorgyi, L. E., Ghazinouri, R., Glowny, M. G., McNeil, K., Kaynor, E. F., Neumann, C., Seidman, C. E., MacRae, C. A., Ho, C. Y., & Lakdawala, N. K. (2019). The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication. *Molecular Genetics & Genomic Medicine*, 7(11), e940. <https://doi.org/10.1002/mgg3.940>
- Helio, T., Elliott, P., Koskenvuo, J. W., Gimeno, J. R., Tavazzi, L., Tendera, M., Kaski, J. P., Mansencal, N., Bilinska, Z., Carr-White, G., Damy, T., Frustaci, A., Kindermann, I., Ripoll-Vera, T., Celutkienė, J., Axelsson, A., Lorenzini, M., Saad, A., Maggioni, A. P., ... EORP Cardiomyopathy Registry Investigators Group. (2020). ESC EORP cardiomyopathy registry: Real-life practice of genetic counselling and testing in adult cardiomyopathy patients. *ESC Heart Failure*, 7(5), 3013–3021. <https://doi.org/10.1002/ehf2.12925>
- Hershberger, R. E., Givertz, M. M., Ho, C. Y., Judge, D. P., Kantor, P. F., McBride, K. L., Morales, A., Taylor, M. R. G., Vatta, M., & Ware, S.

- M. (2018). Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. *Journal of Cardiac Failure*, 24(5), 281–302. <https://doi.org/10.1016/j.cardfail.2018.03.004>
- Hickey, K. T., Sciacca, R. R., Biviano, A. B., Whang, W., Dizon, J. M., Garan, H., & Chung, W. K. (2014). The effect of cardiac genetic testing on psychological well-being and illness perceptions. *Heart & Lung*, 43(2), 127–132. <https://doi.org/10.1016/j.hrtlng.2014.01.006>
- Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A., Cochrane Bias Methods Group, & Cochrane Statistical Methods Group. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*, 343, 5928. <https://doi.org/10.1136/bmj.d5928>
- Hudson, J., Sturm, A. C., Salberg, L., Brennan, S., Quinn, G. P., & Vadaparampil, S. T. (2019). Disclosure of diagnosis to at-risk relatives by individuals diagnosed with hypertrophic cardiomyopathy (HCM). *Journal of Community Genetics*, 10(2), 207–217. <https://doi.org/10.1007/s12687-018-0377-1>
- Ingles, J., McGaughan, J., Scuffham, P. A., Atherton, J., & Semsarian, C. (2012). A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. *Heart*, 98(8), 625–630. <https://doi.org/10.1136/heartjnl-2011-300368>
- Ingles, J., Yeates, L., O'Brien, L., McGaughan, J., Scuffham, P. A., Atherton, J., & Semsarian, C. (2012). Genetic testing for inherited heart diseases: Longitudinal impact on health-related quality of life. *Genetics in Medicine*, 14(8), 749–752. <https://doi.org/10.1038/gim.2012.47>
- Ison, H. E., Ware, S. M., Schwantes-An, T. H., Freeze, S., Elmore, L., & Spoonamore, K. G. (2019). The impact of cardiovascular genetic counseling on patient empowerment. *Journal of Genetic Counseling*, 28(3), 570–577. <https://doi.org/10.1002/jgc4.1050>
- Jensen, M. K., Havndrup, O., Christiansen, M., Andersen, P. S., Diness, B., Axelsson, A., Skovby, F., Kober, L., & Bundgaard, H. (2013). Penetrance of hypertrophic cardiomyopathy in children and adolescents: A 12-year follow-up study of clinical screening and predictive genetic testing. *Circulation*, 127(1), 48–54. <https://doi.org/10.1161/CIRCULATIONAHA.111.090514>
- Jujavarapu, C., Anandasakaran, J., Amendola, L. M., Haas, C., Zampino, E., Henrikson, N. B., Jarvik, G. P., & Mooney, S. D. (2021). ShareDNA: A smartphone app to facilitate family communication of genetic results. *BMC Medical Genomics*, 14(1), 10. <https://doi.org/10.1186/s12920-020-00864-0>
- Khouzam, A., Kwan, A., Baxter, S., & Bernstein, J. A. (2015). Factors associated with uptake of genetics services for hypertrophic cardiomyopathy. *Journal of Genetic Counseling*, 24(5), 797–809. <https://doi.org/10.1007/s10897-014-9810-8>
- Knight, L. M., Miller, E., Kovach, J., Arscott, P., von Alvensleben, J. C., Bradley, D., Valdes, S. O., Ware, S. M., Meyers, L., Travers, C. D., Campbell, R. M., & Etheridge, S. P. (2020). Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic cardiomyopathy. *Heart Rhythm*, 17(1), 106–112. <https://doi.org/10.1016/j.hrthm.2019.06.015>
- Ko, C., Arscott, P., Concannon, M., Saberi, S., Day, S. M., Yashar, B. M., & Helms, A. S. (2018). Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup. *Genetics in Medicine*, 20(1), 69–75. <https://doi.org/10.1038/gim.2017.79>
- Landstrom, A. P., Kim, J. J., Gelb, B. D., Helm, B. M., Kannankeril, P. J., Semsarian, C., Sturm, A. C., Tristani-Firouzi, M., Ware, S. M., on behalf of the American Heart Association Council on Genomic and Precision Medicine, & Council on Lifelong Congenital Heart Disease and Heart Health in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Lifestyle and Cardiometabolic Health. (2021). Genetic testing for heritable cardiovascular diseases in pediatric patients: A scientific statement from the American Heart Association. *Circulation. Genomic and precision medicine*, 14(5), e000086. <https://doi.org/10.1161/HCG.0000000000000086>
- MacLeod, R., Beach, A., Henriques, S., Knopp, J., Nelson, K., & Kerzin-Storarr, L. (2014). Experiences of predictive testing in young people at risk of Huntington's disease, familial cardiomyopathy or hereditary breast and ovarian cancer. *European Journal of Human Genetics*, 22(3), 396–401. <https://doi.org/10.1038/ejhg.2013.143>
- Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. *Circulation*, 92(4), 785–789. <https://doi.org/10.1161/01.cir.92.4.785>
- Mathew, J., Zahavich, L., Lafreniere-Roula, M., Wilson, J., George, K., Benson, L., Bowdin, S., & Mital, S. (2018). Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. *Clinical Genetics*, 93(2), 310–319. <https://doi.org/10.1111/cge.13157>
- Murphy, S. L., Anderson, J. H., Kapplinger, J. D., Kruisselbrink, T. M., Gersh, B. J., Ommen, S. R., Ackerman, M. J., & Bos, J. M. (2016). Evaluation of the Mayo Clinic phenotype-based genotype predictor score in patients with clinically diagnosed hypertrophic cardiomyopathy. *Journal of Cardiovascular Translational Research*, 9(2), 153–161. <https://doi.org/10.1007/s12265-016-9681-5>
- Musunuru, K., Hershberger, R. E., Day, S. M., Klinedinst, N. J., Landstrom, A. P., Parikh, V. N., Prakash, S., Semsarian, C., Sturm, A. C., American Heart Association Council on Genomic and Precision Medicine, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular and Stroke Nursing, & Council on Clinical Cardiology. (2020). Genetic testing for inherited cardiovascular diseases: A scientific statement from the American Heart Association. *Circulation. Genomic and Precision Medicine*, 13(4), e000067. <https://doi.org/10.1161/HCG.0000000000000067>
- Nieuwhof, K., Birnie, E., van den Berg, M. P., de Boer, R. A., van Haelst, P. L., van Tintelen, J. P., & van Langen, I. M. (2017). Follow-up care by a genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: A randomised comparison. *European Journal of Human Genetics*, 25(2), 169–175. <https://doi.org/10.1038/ejhg.2016.155>
- Norrish, G., Jager, J., Field, E., Quinn, E., Fell, H., Lord, E., Cicerchia, M. N., Ochoa, J. P., Cervi, E., Elliott, P. M., & Kaski, J. P. (2019). Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives. *Circulation*, 140(3), 184–192. <https://doi.org/10.1161/CIRCULATIONAHA.118.038846>
- Oliveri, S., Ferrari, F., Manfrinati, A., & Pravettoni, G. (2018). A systematic review of the psychological implications of genetic testing: A comparative analysis among cardiovascular neurodegenerative and cancer diseases. *Frontiers in Genetics*, 9, 624. <https://doi.org/10.3389/fgene.2018.00624>
- Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., Kimmelstiel, C., Kittleson, M., Link, M. S., Maron, M. S., Martinez, M. W., Miyake, C. Y., Schaff, H. V., Semsarian, C., & Sorajja, P. (2021). 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. *The Journal of Thoracic and Cardiovascular Surgery*, 162(1), e23–e106. <https://doi.org/10.1016/j.jtcvs.2021.04.001>
- Ormondroyd, E., Oates, S., Parker, M., Blair, E., & Watkins, H. (2014). Pre-symptomatic genetic testing for inherited cardiac conditions: A qualitative exploration of psychosocial and ethical implications. *European Journal of Human Genetics*, 22(1), 88–93. <https://doi.org/10.1038/ejhg.2013.81>
- Otten, E., Birnie, E., Ranchor, A. V., van Tintelen, J. P., & van Langen, I. M. (2015). A group approach to genetic counselling of cardiomyopathy patients: Satisfaction and psychological outcomes sufficient

- for further implementation. *European Journal of Human Genetics*, 23(11), 1462–1467. <https://doi.org/10.1038/ejhg.2015.10>
- Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan—a web and mobile app for systematic reviews. *Systematic Reviews*, 5(1), 210. <https://doi.org/10.1186/s13643-016-0384-4>
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hrobjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>
- R Core Team. (2021). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing. <https://www.R-project.org/>
- Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Hahn, S. E., Strecker, M. N., & Williams, J. L. (2006). A new definition of genetic counseling: National Society of Genetic Counselors' task force report. *Journal of Genetic Counseling*, 15(2), 77–83. <https://doi.org/10.1007/s10897-005-9014-3>
- Schmidlen, T., Schwartz, M., DiLoreto, K., Kirchner, H. L., & Sturm, A. C. (2019). Patient assessment of chatbots for the scalable delivery of genetic counseling. *Journal of Genetic Counseling*, 28(6), 1166–1177. <https://doi.org/10.1002/jgc4.1169>
- Schwarzer, G., Chaimaitelly, H., Abu-Raddad, L. J., & Rucker, G. (2019). Seriously misleading results using inverse of freeman-Tukey double arcsine transformation in meta-analysis of single proportions. *Research Synthesis Methods*, 10(3), 476–483. <https://doi.org/10.1002/jrsm.1348>
- Spanaki, A., O'Curry, S., Winter-Beatty, J., Mead-Regan, S., Hawkins, K., English, J., Head, C., Ridout, D., Tome-Esteban, M. T., Elliott, P., & Kaski, J. P. (2016). Psychosocial adjustment and quality of life in children undergoing screening in a specialist paediatric hypertrophic cardiomyopathy clinic. *Cardiology in the Young*, 26(5), 961–967. <https://doi.org/10.1017/S1047951115001717>
- Sturm, A. C. (2016). Cardiovascular cascade genetic testing: Exploring the role of direct contact and technology. *Frontiers in Cardiovascular Medicine*, 3, 11. <https://doi.org/10.3389/fcvm.2016.00011>
- Tomasov, P., Minarik, M., Zemanek, D., Cadova, P., Homolova, S., Curilka, K., Penicka, M., Benesova, L., Belsanova, B., Gregor, P., & Veselka, J. (2014). Genetic testing in the management of relatives of patients with hypertrophic cardiomyopathy. *Folia Biologica*, 60(1), 28–34. FB2014A0004 [pii].
- Tunca Sahin, G., Ozgur, S., Kafali, H. C., Sevinc Sengul, F., Haydin, S., Guzeltas, A., & Ergul, Y. (2021). Clinical characteristics of hypertrophic cardiomyopathy in children: An 8-year single center experience. *Pediatrics International*, 63(1), 37–45. <https://doi.org/10.1111/ped.14393>
- van den Heuvel, L. M., van Teijlingen, M. O., van der Roest, W., van Langen, I. M., Smets, E. M. A., van Tintelen, J. P., & Christiaans, I. (2020). Long-term follow-up study on the uptake of genetic counseling and predictive DNA testing in inherited cardiac conditions. *Circulation. Genomic and Precision Medicine*, 13(5), 524–530. <https://doi.org/10.1161/CIRCGEN.119.002803>
- van der Roest, W. P., Pennings, J. M., Bakker, M., van den Berg, M. P., & van Tintelen, J. P. (2009). Family letters are an effective way to inform relatives about inherited cardiac disease. *American Journal of Medical Genetics. Part A*, 149A(3), 357–363. <https://doi.org/10.1002/ajmg.a.32672>
- Vermeer, A. M. C., Clur, S. B., Blom, N. A., Wilde, A. A. M., & Christiaans, I. (2017). Penetrance of hypertrophic cardiomyopathy in children who are mutation positive. *The Journal of Pediatrics*, 188, 91–95. <https://doi.org/10.1016/j.jpeds.2017.03.033>
- Viechtbauer, W. (2010). Conducting Meta-Analyses in R with the metafor Package. *Journal of Statistical Software*, 36(3), 1–48. <https://doi.org/10.18637/jss.v036.i03>
- Wells, G. S., O'Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2013). *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses*. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
- Wordsworth, S., Leal, J., Blair, E., Legood, R., Thomson, K., Seller, A., Taylor, J., & Watkins, H. (2010). DNA testing for hypertrophic cardiomyopathy: A cost-effectiveness model. *European Heart Journal*, 31(8), 926–935. <https://doi.org/10.1093/eurheartj/ehq067>
- Wynn, J., Holland, D. T., Duong, J., Ahimaz, P., & Chung, W. K. (2018). Examining the psychosocial impact of genetic testing for cardiomyopathies. *Journal of Genetic Counseling*, 27(4), 927–934. <https://doi.org/10.1007/s10897-017-0186-4>
- Zhu, C., Wang, S., Ma, Y., Wang, S., Zhou, Z., Song, Y., Yan, J., Meng, Y., & Nie, C. (2020). Childhood hypertrophic obstructive cardiomyopathy and its relevant surgical outcome. *The Annals of Thoracic Surgery*, 110(1), 207–213. <https://doi.org/10.1016/j.athoracsur.2019.10.016>

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Cirino, A. L., Harris, S. L., Murad, A. M., Hansen, B., Malinowski, J., Natoli, J. L., Kelly, M. A., & Christian, S. (2022). The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy—A systematic review and meta-analysis. *Journal of Genetic Counseling*, 31, 1290–1305. <https://doi.org/10.1002/jgc4.1604>